Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
Authors' conclusion
In this post hoc analysis, people with T2D experienced substantially longer continuous time in glycaemic control and more sustained body weight reductions with tirzepatide versus placebo and active comparators.
Study context
- Population
- Participants with T2D from SURPASS 1–5SURPASS 1–5
- Participants
- 6,246 participants
- Comparison
- Once-weekly tirzepatide vs comparators
- Primary endpoint
- Continuous time spent with HbA1c <7.0% (53 mmol/mol), ≤6.5% (48 mmol/mol), ≥5% body weight reduction, and combined HbA1c ≤6.5% with ≥5% body weight reduction
- Follow-up
- 40 weeks (SURPASS-1, −2, −5) or 52 weeks (SURPASS-3, −4)
Methodological detailsparticipant-level, exploratory
- Participant-level
- Exploratory
Primary result
As reported in the abstract
Median time spent with HbA1c <7.0% (53 mmol/mol), % of treatment duration
40-week studies: tirzepatide vs semaglutide vs placebo
80% vs 70% vs 0%
52-week studies: tirzepatide vs insulin degludec vs insulin glargine (p < 0.001)
77%-85% vs 62% vs 23%
Further findings
| Outcome | Tirzepatide | SemaglutideMedian | P value |
|---|---|---|---|
| Median time spent with ≥5% body weight reduction | median 20%-77% | 25% | P < 0.001 |
| Median time spent with HbA1c ≤6.5% (48 mmol/mol) and ≥5% body weight reductionLonger with tirzepatide | median 35%-60% | 7% | P < 0.001 |
Median time spent with ≥5% body weight reduction
- Dose-dependent increases in time with ≥5% body weight reduction with tirzepatide
Original publication
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme. Diabetes Obes Metab. Published 13 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →